February 2025
FDA Approves Vertex’s Journavx: First Non-Opioid Pain Medication in Decades
Journavx, suzetrigine, non-opioid, acute pain, FDA approval, Vertex Pharmaceuticals, pain management, opioid alternative
RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses
Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses
Bristol Myers Squibb and Kyowa Kirin Announce New Rounds of Layoffs in New Jersey
Pharmaceutical layoffs, workforce reduction, cost-cutting measures, Bristol Myers Squibb, Kyowa Kirin, New Jersey pharma industry
Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs
Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)
RFK Jr.’s HHS Secretary Nomination Advances to Full Senate Vote
Robert F. Kennedy Jr., HHS Secretary, Senate Finance Committee, confirmation process, vaccine controversy, Republican support
World Cancer Day 2025: Innovations in Prevention, Detection, and Treatment
cancer research, immunotherapy, early detection, AI in oncology, novel therapies, clinical trials, personalized medicine
Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance
Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance
Senator Cassidy’s Crucial Vote Advances RFK Jr.’s HHS Secretary Nomination
Robert F. Kennedy Jr., Bill Cassidy, HHS Secretary nomination, Senate Finance Committee, vaccine safety, public health, Trump administration
Astellas Pharma Announces Major Management Restructuring Amid Strong Financial Performance
Astellas Pharma, management restructuring, financial results, executive appointments, pharmaceutical industry
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges